Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth O Hexner

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic LeukemiaNoelle V Frey, Saar Gill, Elizabeth O Hexner, et al.
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity ConditioningRan Reshef, Austin P Huffman, Amy Gao, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
American Journal of Hematology|February 10, 2016
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftmentElizabeth O Hexner, Selina M Luger, Ran Reshef, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2020
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic LeukemiaNoelle V Frey, Saar Gill, Elizabeth O Hexner, et al.
American Journal of Hematology|April 4, 2020
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agentsGee Youn Geeny Kim, Jonathan Burns, Craig W Freyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2015
High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity ConditioningRan Reshef, Austin P Huffman, Amy Gao, et al.
Nature Medicine|December 7, 2021
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trialDaniel J DeAngelo, Deepti H Radia, Tracy I George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2019
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic LeukemiaNoelle V Frey, Pamela A Shaw, Elizabeth O Hexner, et al.
Leukemia & Lymphoma|February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamideCraig W Freyer, Alison Carulli, Shannon Gier, et al.
American Journal of Hematology|February 10, 2016
Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftmentElizabeth O Hexner, Selina M Luger, Ran Reshef, et al.
Haematologica|April 18, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemiaMatthew P Connor, Neeharika Prathapa, Noelle V Frey, et al.
Transplantation and Cellular Therapy|May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of StayCraig W Freyer, Shannon Gier, Mary E Moyer, et al.
Leukemia & Lymphoma|January 8, 2015
Phase I dose escalation study of lestaurtinib in patients with myelofibrosisElizabeth O Hexner, John Mascarenhas, Josef Prchal, et al.
Pageof 11